Healthcare Services

Chronic Spontaneous Urticaria Market to Reach $3.2B by 2030 at 7.4% CAGR

April 20, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Chronic Spontaneous Urticaria Market Be By 2030 Compared To Its 2026 Market Size?

The chronic spontaneous urticaria market size has shown significant expansion over recent years. It is projected to increase from $2.23 billion in 2025 to $2.41 billion in 2026, registering a compound annual growth rate (CAGR) of 8.4%. The historical progress in this market is attributable to factors such as the rising prevalence of chronic skin allergies, enhanced availability of second-generation antihistamines, advancements in diagnostic practices, an uptick in dermatology clinic visits, and greater patient awareness regarding urticaria conditions.

The market for chronic spontaneous urticaria is projected to experience substantial expansion in the coming years. Its value is forecast to reach $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This expansion throughout the forecast period stems from factors such as the increasing development of biologic drug pipelines, heightened investment in autoimmune dermatology research, the broader application of targeted monoclonal antibodies, a growing emphasis on achieving symptom-free disease management, and the increased uptake of long-term maintenance therapies. Key trends anticipated during this period encompass the growing embrace of biologic treatments for csu, the rising implementation of advanced antihistamine protocols, a heightened focus on autoimmune disease mechanisms, the development of personalized treatment algorithms, and improved oversight of long-term disease control.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

What Primary Drivers Are Shaping The Chronic Spontaneous Urticaria Market?

A projected rise in alcohol intake is anticipated to stimulate the expansion of the chronic spontaneous urticaria market in the future. This uptick in alcohol use can be linked to multiple elements, including societal standards, pressure, promotional activities, cost-effectiveness, and accessibility. For certain people, consuming alcohol may worsen the signs of chronic spontaneous urticaria, resulting in more pronounced hives and swelling. As an illustration, for 2025, a 2023 poll by the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, revealed that 25% of UK individuals aged 18–24 now completely abstain from alcohol, underscoring a significant move toward abstinence within the younger demographic. Consequently, a rise in alcohol intake is propelling the expansion of the chronic spontaneous urticaria market.

How Is The Chronic Spontaneous Urticaria Market Organized By Segment Classification?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy

What Trends Are Affecting The Growth Of The Chronic Spontaneous Urticaria Market?

Key firms within the chronic spontaneous urticaria market are working on advanced next-generation Briquilimab (JSP191) with the goal of improving treatment effectiveness and decreasing how often doses are needed. This next-generation Briquilimab (JSP191) is a monoclonal antibody engineered to specifically target and eliminate certain immune cells, especially those expressing CD47, relevant for conditions like chronic spontaneous urticaria. As an illustration, in November 2023, Jasper Therapeutics Inc., a clinical-stage biotechnology company based in the US, reported the administration of the first dose to a patient in its Phase 1b/2a clinical study investigating Briquilimab for chronic spontaneous urticaria (CSU). This milestone is vital for evaluating the safety and efficacy of Briquilimab, a next-generation monoclonal antibody that targets CD47, in managing this persistent issue of hives and itching. The primary objective of the study is to determine Briquilimab’s capacity to mitigate symptoms and enhance the life quality of individuals affected by CSU.

Who Are The Industry Participants Involved In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Get The Full Chronic Spontaneous Urticaria Market Report:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Region Holds The Highest Market Share In The Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Chronic Spontaneous Urticaria Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2026, By The Business Research Company

Atopic Dermatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Allergic Rhinitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795